pubmed:abstractText |
Visualization of the CD20-antigen expression could provide a tool to localize sites of inflammation and could be of additive value in the diagnosis, and subsequently, in the treatment follow-up of patients with rheumatoid arthritis. In this study, an anti-CD20 monoclonal antibody, rituximab (Mabthera®), was radiolabeled with ¹²?Iodine. We report the first results of I¹²?-rituximab PET/CT in patients with rheumatoid arthritis.
|